Summary by Futu AI
Mei Vaccine Co., Ltd. (Mei Vaccine) recently announced that the Phase III clinical trial data of its developed serum-free iterative rabies vaccine has completed unblinding and statistical analysis, showing good immunogenicity and safety, achieving clinical preset goals. The vaccine does not contain animal serum, significantly improving safety and reducing the probability of adverse reactions, with the potential to become the world's first serum-free rabies vaccine on the market. Mei Vaccine has completed the construction of production workshops, meeting international standards, and has conducted process verifications that meet the requirements for listing scale and quality. Currently, the company is actively progressing towards obtaining the clinical summary report for submission to the National Medical Products Administration (NMPA) for drug registration. As the world's second-largest rabies vaccine supplier, Mei Vaccine's technological iteration upgrade will provide the market with higher quality and safer vaccine products.
